JERSEY CITY, N.J. — August 13, 2025 — Leads & Copy — SCYNEXIS, Inc. (NASDAQ: SCYX) announced the first new patient dosed in its Phase 3 MARIO study, triggering a $10M milestone payment from GSK, following the lifting of the FDA clinical hold. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as previously disclosed GSK disputes these milestone payments. The company is also working with GSK to transfer the BREXAFEMME New Drug Application (NDA) by year-end, ahead of anticipated GSK Regulatory interactions in 2026 to discuss the relaunch of the product. SCYNEXIS anticipates reporting Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) data for SCY-247 (oral) in Q3 2025.
The court granted SCYNEXIS’ motion to dismiss the November 2023 securities class action with leave to amend on July 30, 2025. The company ended Q2 2025 with $46.5 million in cash, cash equivalents, and investments, projecting a cash runway into Q4 2026.
For the three months ended June 30, 2025, revenue primarily consisted of $1.4 million in license agreement revenue associated with the GSK License Agreement. Research and development expenses were $7.1 million, and selling, general and administrative expenses increased to $3.8 million. Net loss for the quarter was $6.9 million, or $(0.14) basic loss per share.
David Angulo, M.D., President and Chief Executive Officer, said the company is excited about the continued progress of SCY-247 and remains committed to resolving the dispute with GSK regarding milestone payments.
Contact:
Irina Koffler
LifeSci Advisors
Tel: 917-734-7387
ikoffler@lifesciadvisors.com
Source: SCYNEXIS, Inc.
